Lantheus (NASDAQ:LNTH) Trading Up 5.1% – Time to Buy?

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s stock price rose 5.1% during mid-day trading on Monday . The company traded as high as $114.26 and last traded at $113.49. Approximately 195,166 shares traded hands during mid-day trading, a decline of 79% from the average daily volume of 949,610 shares. The stock had previously closed at $107.98.

Analysts Set New Price Targets

LNTH has been the subject of a number of research analyst reports. B. Riley lifted their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Redburn Atlantic assumed coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price for the company. JMP Securities lowered their target price on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research note on Thursday, August 1st. Truist Financial lowered their target price on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Finally, Leerink Partners boosted their target price on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Lantheus Stock Up 6.5 %

The stock’s fifty day simple moving average is $108.13 and its two-hundred day simple moving average is $94.87. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The company has a market capitalization of $7.98 billion, a price-to-earnings ratio of 18.91 and a beta of 0.51.

Insiders Place Their Bets

In other news, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, President Paul Blanchfield sold 2,000 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the transaction, the president now owns 98,980 shares in the company, valued at $9,540,682.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Lantheus

Large investors have recently made changes to their positions in the company. Daiwa Securities Group Inc. bought a new stake in Lantheus during the first quarter worth approximately $1,269,000. Nordea Investment Management AB raised its stake in shares of Lantheus by 42.6% in the first quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider’s stock valued at $2,932,000 after purchasing an additional 14,147 shares in the last quarter. Hancock Whitney Corp raised its stake in shares of Lantheus by 265.6% in the first quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock valued at $1,254,000 after purchasing an additional 14,639 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Lantheus in the second quarter valued at $290,000. Finally, Pitcairn Co. raised its stake in shares of Lantheus by 117.0% in the first quarter. Pitcairn Co. now owns 8,364 shares of the medical equipment provider’s stock valued at $521,000 after purchasing an additional 4,509 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.